{"gene":"TRPV4","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2002,"finding":"4α-Phorbol 12,13-didecanoate (4α-PDD) directly gates TRPV4 as an agonist, activating an outwardly rectifying, Ca2+-permeable cation channel (PCa/PNa ≈ 5.8) in cells expressing hVRL-2/mTRP12; this activation is independent of protein kinase C and is modulated by intracellular Ca2+ (inhibitory IC50 ≈ 406 nM). Ruthenium Red blocks inward currents in a voltage-dependent manner.","method":"Whole-cell patch-clamp and Ca2+ imaging in stably/transiently transfected 1321N1 and HEK-293 cells; pharmacological PKC dissection; native aortic endothelial cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct electrophysiological reconstitution in heterologous system with pharmacological dissection, replicated across two cell lines and native tissue","pmids":["11827975"],"is_preprint":false},{"year":2002,"finding":"Asp672 and Asp682 in the pore region are critical determinants of Ca2+ permeability and outward rectification; Met680 at the putative selectivity filter is essential for current amplitude and Ca2+ permeation; Asp682 (but not Asp672) controls Ruthenium Red affinity; Lys675 (the only positive pore residue) is dispensable for pore function.","method":"Site-directed mutagenesis combined with whole-cell patch-clamp and ion substitution reversal-potential measurements in transfected HEK-293 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — structure-function reconstitution with systematic mutagenesis of multiple residues, multiple orthogonal readouts in one rigorous study","pmids":["12093812"],"is_preprint":false},{"year":2000,"finding":"Trp12 (murine TRPV4 ortholog) forms a Ca2+-permeable channel: heterologous expression elevates basal cytosolic Ca2+ and confers a further increase upon hypoosmotic stimulation, establishing osmosensory gating of this channel.","method":"Heterologous expression in transfected cells with cytosolic Ca2+ measurements under hypoosmotic challenge","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional expression in heterologous system with osmotic challenge, single lab, two readouts (basal Ca2+ elevation and hypotonicity response)","pmids":["11094154"],"is_preprint":false},{"year":2001,"finding":"Heterologous expression of TRP12/OTRPC4 (TRPV4) in HEK-293 cells produces a swelling-activated cation current with Eisenman-IV permeability sequence (PK>PCs>PNa>PLi); overexpression simultaneously down-regulates the endogenous volume-regulated anion channel (VRAC). Unlike VRAC, TRP12 is not activated by reduced intracellular ionic strength or intracellular GTPγS at constant volume.","method":"Whole-cell patch-clamp in transfected HEK-293 cells with hypotonic swelling; ionic substitution; pharmacological and ionic-strength manipulations","journal":"Pflugers Archiv : European journal of physiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous electrophysiological reconstitution with multiple negative controls; single lab but multiple orthogonal methods","pmids":["11713648"],"is_preprint":false},{"year":2021,"finding":"TRPV4 physically interacts with RhoA via the TRPV4 N-terminal ankyrin repeat domain; this interaction suppresses TRPV4 channel activity and inhibits RhoA activation, thereby promoting neurite extension. Neuropathy-causing (but not skeletal dysplasia) mutations in the N-terminal domain disrupt TRPV4-RhoA binding, impairing cytoskeletal outgrowth. RhoA inhibition rescues neurite length both in vitro and in a Drosophila model of TRPV4 neuropathy.","method":"Unbiased protein interaction screen, Co-IP, functional channel recordings, neurite-outgrowth assays with disease-associated point mutants, Drosophila in vivo rescue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, functional channel assay, mutagenesis, two model systems (mammalian cells and Drosophila); multiple orthogonal methods across one study","pmids":["33664271"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structure of human TRPV4 in complex with GTPase RhoA shows RhoA contacts the membrane-facing surface of the TRPV4 ankyrin repeat domains. The agonist 4α-PDD and inhibitor HC-067047 bind at the base of the S1-S4 bundle (voltage-sensing-like domain): 4α-PDD binding leads to pore opening, whereas HC-067047 stabilizes a closed state involving a π-to-α helix transition in pore-forming helix S6.","method":"Cryo-EM structure determination with functional validation; binding-site mutagenesis context inferred from disease-mutation mapping at the RhoA interface","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure with ligand-bound states and functional mechanistic interpretation; disease-mutation mapping provides orthogonal validation","pmids":["37353478"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structures of human TRPV4 with two potent antagonists reveal both ligands bind the voltage-sensing-like domain (VSLD) and stabilize closed channel states; one antagonist occupies the canonical VSLD pocket and the other a novel extended VSLD pocket. Antagonist binding induces a fourfold-to-twofold symmetry transition in the channel.","method":"Cryo-EM structure determination complemented with functional electrophysiology and molecular dynamics simulation","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM with two distinct antagonist complexes, functional data, and MD simulation in one study","pmids":["38659239"],"is_preprint":false},{"year":2019,"finding":"TRPV4 stimulation with GSK1016790A decreases plasma-membrane TRPV4 density within ~20 min through translocation to recycling endosomes via two modes of vesicular fusion; surface density is regulated by intracellular Ca2+ release and controlled by a PI3K/PKC/RhoA signaling pathway.","method":"Single-molecule imaging, live-cell fluorescence, pharmacological inhibition of PI3K, PKC, RhoA in transfected cells","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single-molecule trafficking analysis plus pharmacological pathway dissection; single lab, multiple imaging methods","pmids":["30728775"],"is_preprint":false},{"year":2009,"finding":"Progesterone, acting through the progesterone receptor (PR), transcriptionally represses TRPV4 expression; PR activation reduces TRPV4 mRNA, protein, and 4α-PDD-evoked currents/Ca2+ signals in airway and mammary epithelial cells. The effect is reversed by the PR antagonist RU-486 or siRNA knockdown of both PRA and PRB isoforms. PR co-expression suppresses TRPV4 promoter-driven reporter activity.","method":"RT-PCR, Western blot, whole-cell patch-clamp, Ca2+ imaging, siRNA knockdown, promoter-luciferase reporter assays","journal":"Pflugers Archiv : European journal of physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (mRNA, protein, electrophysiology, Ca2+ imaging, reporter assay, siRNA), single lab","pmids":["19701771"],"is_preprint":false},{"year":2021,"finding":"TRPV4-mediated Ca2+ influx functionally couples to the Ca2+-activated phospholipid scramblase TMEM16F within Ca2+ microdomains in human trophoblasts, driving TMEM16F activation and subsequent trophoblast syncytialization. Pharmacological inhibition or gene silencing of TRPV4 reduces TMEM16F activation and cell fusion.","method":"Patch-clamp electrophysiology, pharmacological agonist/antagonist, siRNA knockdown, cell fusion assays in human trophoblast cell line","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal pharmacological and genetic (siRNA) evidence with electrophysiological Ca2+-microdomain characterization; multiple orthogonal methods in one study","pmids":["35670667"],"is_preprint":false},{"year":2021,"finding":"Depolarized mitochondria switch TRPV4-evoked Ca2+ signaling from IP3R-dependent Ca2+-induced Ca2+ release to mitochondria-independent Ca2+ waves mediated by ATP release through pannexin channels, which then activate purinergic receptors to trigger IP3 store release. This identifies mitochondria as regulators of TRPV4-Ca2+ signal mode in endothelial cells.","method":"Ca2+ imaging (Cal520) in rat mesenteric artery endothelium; pharmacological dissection with CCCP, rotenone, oligomycin, HC067047, U73122, caffeine, suramin, apyrase, probenecid","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — native tissue preparation with systematic pharmacological dissection; single lab, multiple mechanistic probes","pmids":["34605007"],"is_preprint":false},{"year":2023,"finding":"Microglial TRPV4 mediates microglial activation and proliferation after nerve injury, and promotes excitatory spinal neuron plasticity through release of lipocalin-2, linking peripheral nerve injury to central sensitization and neuropathic pain.","method":"Genetic ablation (Trpv4 KO) and pharmacological blockade in spared nerve injury mouse model; lipocalin-2 measurement; electrophysiological and morphological assessment of spinal neurons","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus pharmacological inhibition with defined cellular phenotype and identified downstream mediator (lipocalin-2); single lab","pmids":["36701202"],"is_preprint":false},{"year":2021,"finding":"TRPV4 mediates NLRP3 inflammasome activation induced by crystalline (but not non-crystalline) NLRP3 activators in synovial macrophages, driving IL-1β production and crystal-induced gouty arthritis; TRPV4 expression is functionally confirmed in synovial macrophages and upregulated by MSU crystal stimulation.","method":"Whole-cell patch-clamp, live-cell Ca2+ imaging, TRPV4 KO and pharmacological inhibition, in vitro NLRP3 inflammasome assays, in vivo gout models","journal":"Annals of the rheumatic diseases","confidence":"High","confidence_rationale":"Tier 2 / Strong — electrophysiology, genetic deletion, pharmacological inhibition, in vitro and in vivo models, specificity control (non-crystalline activators unaffected); multiple orthogonal approaches","pmids":["34663597"],"is_preprint":false},{"year":2020,"finding":"TRPV4 activates the Cdc42/N-WASP pathway to regulate formation of invadopodia and filopodia at cellular protrusions, promoting glioblastoma cell migration and invasion in vitro and tumor growth in vivo. TRPV4 co-localizes and interacts with F-actin at protrusions.","method":"Co-IP/co-localization with F-actin, TRPV4 siRNA knockdown, pharmacological agonist/antagonist, invasion assays, subcutaneous and intracranial mouse xenograft models","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, KD and pharmacological approaches with in vitro and in vivo readouts; single lab","pmids":["32843668"],"is_preprint":false},{"year":2018,"finding":"TRPV4 activation promotes glioma cell migration and invasion via AKT phosphorylation leading to Rac1 activation; pharmacological TRPV4 agonism enhances and antagonism suppresses this pathway.","method":"Pharmacological agonist (GSK1016790A) and antagonist (HC-067047), Western blot for AKT phosphorylation and Rac1 activation, migration/invasion assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological gain- and loss-of-function with pathway readouts; single lab, single channel activation approach","pmids":["29928875"],"is_preprint":false},{"year":2016,"finding":"TRPV4 is required for breast cancer cell invasion and transendothelial migration (but not proliferation); TRPV4 overexpression promotes cell softness, blebbing, and actin cortex reorganization, reducing cell rigidity.","method":"siRNA knockdown, overexpression, transendothelial migration assays, mouse xenograft, atomic force microscopy/cell stiffness measurements, live imaging","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD and OE with multiple phenotypic readouts including biomechanical measurements; single lab","pmids":["27291497"],"is_preprint":false},{"year":2020,"finding":"TRPV4 calcium influx activates the RhoA/ROCK1 pathway leading to LIMK/cofilin activation, which regulates F-actin and paxillin (PXN) levels, driving endometrial cancer cell migration and invasion.","method":"Proteomic/bioinformatics analysis, overexpression and knockdown, pharmacological Ca2+ manipulation, Western blot for RhoA/ROCK1/LIMK/cofilin/paxillin, migration assays, in vivo xenograft","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway dissection with KD/OE and in vivo confirmation; single lab, multiple biochemical readouts","pmids":["33230171"],"is_preprint":false},{"year":2022,"finding":"TRPV4 activity in astrocytes promotes neuroinflammation through a TRPV4/Ca2+/YAP/STAT3 signaling pathway; YAP siRNA knockdown blocks 4-AP-induced astrocyte reactivity and cytokine release downstream of TRPV4.","method":"siRNA knockdown of TRPV4 and YAP, pharmacological TRPV4 inhibition, Ca2+ imaging, cytokine ELISA, in vivo mouse seizure model and human epileptic tissue analysis","journal":"Neurotherapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (siRNA) and pharmacological approaches in vitro and in vivo with defined pathway (TRPV4/Ca2+/YAP/STAT3); single lab","pmids":["35182379"],"is_preprint":false},{"year":2022,"finding":"Calcium-sensing receptor (CaSR) couples to TRPV4 channels in macrophages via PLA2/cytochrome P450 and PLC/PKC pathways; CaSR activation drives extracellular Ca2+ entry predominantly through TRPV4, and this CaSR-TRPV4 coupling promotes M1 macrophage polarization and cytokine (IL-1β, TNFα) production.","method":"Pharmacological inhibition of CaSR and TRPV4, TRPV4 KO mice peritoneal macrophages, digital Ca2+ imaging, immunofluorescence, ELISA, Western blot, qPCR","journal":"Acta physiologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mice plus pharmacological dissection with pathway intermediates identified; single lab, multiple orthogonal methods","pmids":["36606511"],"is_preprint":false},{"year":2023,"finding":"Endothelial TRPV4 forms a functional complex with eNOS (endothelial nitric oxide synthase); TRPV4-eNOS interaction promotes vasodilation and regulates blood pressure. This interaction is impaired during hypertension, and a small molecule (JNc-463) designed to enhance TRPV4-eNOS interaction restores vasodilation and exerts antihypertensive effects in mice.","method":"Co-immunoprecipitation, immuno-FRET, site-directed mutagenesis to map binding site, endothelium-specific TRPV4 KO mice, single-cell RNA-seq, molecular docking and in vivo pharmacology","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP, FRET, mutagenesis-mapped binding site, endothelium-specific KO, and pharmacological rescue; multiple orthogonal methods in one study","pmids":["34822720"],"is_preprint":false},{"year":2021,"finding":"Retinal microglial TRPV4 activation (by agonist GSK1016790A or hypotonicity) requires intermediary activation of phospholipase A2 (PLA2), cytochrome P450, and epoxyeicosatrienoic acid (EET) production; TRPV4 activation in microglia triggers Ca2+ elevation, outwardly rectifying cation current, and retraction of higher-order processes.","method":"Ca2+ imaging, whole-cell patch-clamp, pharmacological inhibition of PLA2/CYP450/EET pathway and TRPV4 antagonist HC067047 in dissociated and intact microglia","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — electrophysiology and Ca2+ imaging with pharmacological pathway dissection in native retinal microglia; single lab","pmids":["33624376"],"is_preprint":false},{"year":2021,"finding":"Thermosensitive TRPV4 channels mediate temperature-dependent microglial movement within the physiological body temperature range (>34°C activation threshold in brain); TRPV4 deletion abolishes temperature-dependent microglial motility both in vitro and in vivo.","method":"TRPV4 KO mice, live two-photon imaging of microglia in vivo, in vitro motility assays across temperature range, pharmacological TRPV4 inhibition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO validated in vitro and in vivo with two-photon imaging, pharmacological confirmation; multiple orthogonal approaches","pmids":["33888579"],"is_preprint":false},{"year":2016,"finding":"TRPV4 mediates serotonin (5-HT)-evoked itch: TRPV4 KO mice show significantly fewer 5-HT-induced (but not histamine- or SLIGRL-induced) scratching bouts; ~90% of 5-HT-sensitive DRG neurons are TRPV4-immunoreactive; TRPV4 antagonism suppresses 5-HT-evoked Ca2+ responses in DRG neurons.","method":"TRPV4 KO mice behavioral assay, pharmacological antagonist in vivo, Ca2+ imaging in primary DRG neurons, immunostaining","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mice plus pharmacological antagonism with behavioral and cellular readouts; specificity confirmed by negative controls (histamine, SLIGRL unaffected)","pmids":["26763435"],"is_preprint":false},{"year":2018,"finding":"Hypo-osmotic stress increases RANKL and NFATc1 expression in osteoblasts via Ca2+ influx through both TRPM3 and TRPV4; genetic knockdown of Trpv4 (and Trpm3) reduces hypotonic-stress-induced Ca2+ rise and RANKL/NFATc1 expression.","method":"Pharmacological agonists/antagonists of TRPM3 and TRPV4, siRNA/shRNA knockdown, Ca2+ imaging, Western blot in primary mouse osteoblasts and MC3T3-E1 cells","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown plus pharmacological approaches in primary cells; single lab, multiple readouts","pmids":["30328352"],"is_preprint":false},{"year":2021,"finding":"Membrane cholesterol depletion (with MβCD) augments TRPV4 activation by agonist, osmotic swelling, and mechanical strain, and increases plasma-membrane TRPV4 expression. TRPV4 channels reside primarily outside cholesterol-enriched caveolin/lipid-raft domains; cholesterol repletion reverses these effects. MβCD induces TRPV4-dependent currents in Xenopus oocytes.","method":"MβCD cholesterol depletion/repletion, GSK1016790A activation assays, co-immunoprecipitation with caveolin-1, electrophysiology in Xenopus oocytes, confocal imaging in trabecular meshwork cells","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell systems, electrophysiology, Co-IP, pharmacological manipulation; single lab","pmids":["34710431"],"is_preprint":false},{"year":2019,"finding":"TRPV1 and TRPV4 form functional heteromeric channel complexes in retinal microvascular endothelial cells (RMECs), as demonstrated by proximity ligation assay and patch-clamp recording. Inhibition of either channel suppresses in vitro tubulogenesis and reduces retinal neovascularization in vivo in the OIR mouse model.","method":"Proximity ligation assay, patch-clamp electrophysiology, pharmacological inhibition, in vivo OIR mouse model, in vitro angiogenesis assays","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — PLA and electrophysiology establish heteromeric complex; in vitro and in vivo functional data; single lab","pmids":["31369032"],"is_preprint":false},{"year":2022,"finding":"miR-203b-3p activates the 5-HTR2B receptor, leading to PKC-dependent phosphorylation of TRPV4, which triggers itch in sensory neurons and mouse scratch behavior. Genetic deletion or pharmacological antagonism of TRPV4 attenuates this itch response.","method":"TRPV4 KO mice, pharmacological antagonism (HC067047), PKC inhibitor, Ca2+ imaging in DRG neurons, behavioral scratch assays, computer simulation of miRNA-receptor interaction","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological approaches in vivo and in neuronal Ca2+ imaging; PKC-dependent TRPV4 phosphorylation proposed mechanistically; single lab","pmids":["36049541"],"is_preprint":false},{"year":2022,"finding":"TRPV4 activation induces exocytosis in melanoma cells through interactions with ER folding and vesicle trafficking proteins triggered by Ca2+ entry; this is followed by mitochondrial crista morphology changes leading to ferroptosis.","method":"TRPV4-specific agonists, co-IP to identify folding/vesicle trafficking protein interactions, live-cell vesicle imaging, mitochondrial morphology analysis in melanoma A375 cells","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — Co-IP with trafficking proteins and imaging; single lab, mechanistic connections are partially inferred","pmids":["35456964"],"is_preprint":false},{"year":2023,"finding":"Endothelial-specific TRPV4 knockout protects against pressure-overload cardiac hypertrophy by enhancing coronary angiogenesis; mechanistically, TRPV4 downregulation activates matrix stiffness-dependent YAP and VEGFR2 via the Rho/ROCK/LATS kinase pathway, upregulating proangiogenic factors (VEGFα, NOS3, FGF2).","method":"Endothelium-specific TRPV4 KO mice (transverse aortic constriction model), RNA-seq, siRNA, Western blot, qPCR, confocal immunofluorescence, extracellular matrix gels of varying stiffness","journal":"Hypertension","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endothelium-specific KO with RNA-seq and mechanistic pathway validation; single lab, multiple orthogonal methods","pmids":["37702061"],"is_preprint":false},{"year":2021,"finding":"Substrate mechanics and cytoskeletal integrity modulate mechanically evoked TRPV4 currents, and TRPV4 mechanical activation is distinct from PIEZO1 activation in the same cell type; point mutations associated with TRPV4 phosphorylation and arthropathy alter mechanical (but not chemical) channel gating.","method":"Electrophysiology on substrates of varying stiffness, pharmacological cytoskeletal disruption, comparison of disease-associated point mutants for mechanical vs. chemical gating","journal":"Frontiers in bioengineering and biotechnology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — electrophysiological reconstitution with biomaterial substrates and mutagenesis; single lab","pmids":["33537292"],"is_preprint":false},{"year":2021,"finding":"Pharmacological activation of TRPV4 increases canonical TGFβ signaling in chondrocytes in a Ca2+/CamKII-dependent manner; this potentiation only occurs when TRPV4 is activated after (not before) TGFβ stimulation. RNA-seq identifies JUN and SP1 as key transcription factors mediating this crosstalk.","method":"Pharmacological TRPV4 activation/inhibition, CamKII inhibitor, TRPV4 knockdown, TGFβ reporter assays, RNA-seq in chondrocytes","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic (KD) plus transcriptomic analysis with mechanistic Ca2+/CamKII dissection; single lab","pmids":["33805168"],"is_preprint":false}],"current_model":"TRPV4 is a polymodal, Ca2+-permeable non-selective cation channel that is directly gated by cell swelling, heat, 4α-phorbol esters (at the S1-S4/VSLD domain), and epoxyeicosatrienoic acids (via PLA2/cytochrome P450 metabolism); its pore selectivity is determined by residues Asp672, Asp682, and Met680; it physically interacts with RhoA through its N-terminal ankyrin repeat domain (suppressing both TRPV4 channel activity and RhoA activation to regulate cytoskeletal outgrowth and neurite extension), forms a functional complex with eNOS to promote vasodilation, functionally couples to TMEM16F within Ca2+ microdomains to drive cell fusion, and signals through downstream pathways including RhoA/ROCK1, Cdc42/N-WASP, AKT/Rac1, PLC/PKC, and YAP/STAT3 to regulate cytoskeletal remodeling, mechanosensing in bone and cartilage, immune cell activation (including NLRP3 inflammasome-dependent IL-1β release in macrophages), and sensory neuron-mediated pain and itch."},"narrative":{"mechanistic_narrative":"TRPV4 is a polymodal, Ca2+-permeable non-selective cation channel that transduces osmotic, mechanical, thermal, and chemical stimuli into Ca2+-dependent cellular responses governing cytoskeletal remodeling, vascular tone, mechanosensing, immune activation, and sensory signaling [PMID:11094154, PMID:11827975, PMID:33888579]. The channel is directly gated by hypotonic cell swelling, producing a swelling-activated cation current with an Eisenman-IV permeability sequence distinct from volume-regulated anion channels [PMID:11713648, PMID:11094154], and by the synthetic agonist 4α-PDD, which binds the base of the S1-S4 voltage-sensing-like domain (VSLD) to open the pore independently of PKC [PMID:11827975, PMID:37353478]; antagonists such as HC-067047 bind the same VSLD and stabilize closed states via a π-to-α transition in the pore helix S6 and a fourfold-to-twofold symmetry change [PMID:37353478, PMID:38659239]. Pore residues Asp672, Asp682, and Met680 set Ca2+ permeability, outward rectification, and Ruthenium Red sensitivity [PMID:12093812]. The cytosolic N-terminal ankyrin repeat domain physically binds RhoA, an interaction that mutually suppresses channel activity and RhoA activation to promote neurite extension; neuropathy-associated mutations disrupt this interface, and cryo-EM places RhoA on the membrane-facing surface of the ankyrin repeats [PMID:33664271, PMID:37353478]. Downstream of Ca2+ influx, TRPV4 drives cytoskeletal and migratory programs through RhoA/ROCK1/LIMK/cofilin [PMID:33230171], Cdc42/N-WASP [PMID:32843668], and AKT/Rac1 [PMID:29928875], and contributes to mechanosensing and matrix-stiffness signaling via YAP [PMID:37702061, PMID:35182379]. TRPV4 forms functional complexes with eNOS to promote vasodilation and regulate blood pressure [PMID:34822720] and couples to the scramblase TMEM16F within Ca2+ microdomains to drive cell fusion [PMID:35670667]. In immune and glial cells it mediates crystal-induced NLRP3 inflammasome activation and IL-1β release in macrophages [PMID:34663597], CaSR-coupled M1 polarization [PMID:36606511], and microglial activation and motility [PMID:33888579, PMID:36701202], and in sensory neurons it mediates serotonin-evoked itch [PMID:26763435, PMID:36049541]. Channel surface density and gating are tuned by Ca2+/PI3K/PKC/RhoA-dependent endosomal trafficking [PMID:30728775], membrane cholesterol content [PMID:34710431], and transcriptional repression by the progesterone receptor [PMID:19701771].","teleology":[{"year":2000,"claim":"Established that the murine TRPV4 ortholog is itself an osmosensitive Ca2+-permeable channel, defining its founding function as an osmosensor rather than an accessory subunit.","evidence":"Heterologous expression with cytosolic Ca2+ measurement under hypoosmotic challenge","pmids":["11094154"],"confidence":"Medium","gaps":["Single readout system did not resolve direct vs. indirect osmotic gating","No biophysical pore characterization"]},{"year":2001,"claim":"Defined the biophysical signature of swelling-activated TRPV4 current and distinguished it from the endogenous volume-regulated anion channel, clarifying channel identity.","evidence":"Whole-cell patch-clamp with ionic substitution and ionic-strength/GTPγS controls in HEK-293","pmids":["11713648"],"confidence":"High","gaps":["Mechanism linking swelling to gating not resolved","Did not identify pore residues"]},{"year":2002,"claim":"Identified a direct small-molecule agonist (4α-PDD) and the pore residues governing ion selectivity, converting TRPV4 into a pharmacologically and structurally tractable channel.","evidence":"Patch-clamp + Ca2+ imaging with PKC dissection (4α-PDD); site-directed mutagenesis of pore residues with reversal-potential measurements","pmids":["11827975","12093812"],"confidence":"High","gaps":["Agonist binding site not localized at atomic resolution in these studies","Physiological agonist remained undefined"]},{"year":2009,"claim":"Showed that TRPV4 abundance is transcriptionally controlled by the progesterone receptor, establishing hormonal regulation of channel expression.","evidence":"RT-PCR, Western blot, patch-clamp, Ca2+ imaging, siRNA, promoter-luciferase reporter in epithelial cells","pmids":["19701771"],"confidence":"High","gaps":["Direct vs. indirect promoter binding not resolved","Physiological contexts of PR-TRPV4 regulation limited"]},{"year":2016,"claim":"Connected TRPV4 to cytoskeletal mechanics and cancer cell invasion, showing channel activity reshapes the actin cortex and enables transendothelial migration and serotonin-evoked itch in distinct tissues.","evidence":"siRNA/overexpression with AFM stiffness measurement and xenografts (breast cancer); TRPV4 KO behavioral and DRG Ca2+ imaging (itch)","pmids":["27291497","26763435"],"confidence":"High","gaps":["Molecular link between channel and cortex remodeling not fully defined","Itch transduction pathway upstream of TRPV4 unresolved at this stage"]},{"year":2018,"claim":"Mapped TRPV4 onto specific migratory and mechanotransduction effector pathways (AKT/Rac1; osteoblast RANKL/NFATc1), defining downstream signaling outputs.","evidence":"Pharmacological gain/loss-of-function with phospho-signaling Western blots (glioma); siRNA/shRNA and Ca2+ imaging in osteoblasts","pmids":["29928875","30328352"],"confidence":"Medium","gaps":["Direct vs. indirect coupling to AKT not established","Contribution of co-acting channels (TRPM3) not fully separated"]},{"year":2019,"claim":"Revealed TRPV4 surface density is dynamically regulated by Ca2+/PI3K/PKC/RhoA-dependent endosomal trafficking, and that TRPV4 can form heteromeric complexes with TRPV1.","evidence":"Single-molecule trafficking imaging with pathway inhibitors; proximity ligation assay and patch-clamp for TRPV1/TRPV4 heteromers","pmids":["30728775","31369032"],"confidence":"Medium","gaps":["Stoichiometry of heteromers undefined","Trafficking determinants on TRPV4 not mapped"]},{"year":2021,"claim":"Identified the TRPV4 N-terminal ankyrin domain as a direct RhoA-binding interface that reciprocally controls channel activity and cytoskeletal outgrowth, providing a molecular basis for TRPV4 neuropathy.","evidence":"Unbiased interaction screen, reciprocal Co-IP, channel recordings, disease-mutant neurite assays, Drosophila rescue","pmids":["33664271"],"confidence":"High","gaps":["Structural details of the interface not yet resolved in this study","Skeletal dysplasia mutations act through a distinct mechanism left undefined"]},{"year":2021,"claim":"Expanded TRPV4 into immune, glial, microdomain, and lipid-signaling roles, showing it drives crystal-induced NLRP3/IL-1β in macrophages, couples to TMEM16F for cell fusion, mediates thermosensitive microglial motility, and requires PLA2/CYP450/EET intermediates in microglia.","evidence":"TRPV4 KO + patch-clamp + in vivo gout models; Ca2+-microdomain electrophysiology and fusion assays; KO two-photon imaging; pharmacological PLA2/CYP450 pathway dissection","pmids":["34663597","35670667","33888579","33624376"],"confidence":"High","gaps":["Physical proximity of TRPV4 to TMEM16F not structurally resolved","Mechanism linking crystal sensing to TRPV4 gating undefined","Source/identity of endogenous EET ligand in vivo unclear"]},{"year":2022,"claim":"Defined receptor-coupled and transcriptional effector arms of TRPV4 signaling, including CaSR coupling for M1 polarization, 5-HTR2B/PKC phosphorylation in itch, and YAP/STAT3-driven neuroinflammation.","evidence":"KO macrophages + pharmacology + ELISA (CaSR); KO/antagonist + DRG Ca2+ imaging + PKC inhibitor (itch); siRNA of TRPV4/YAP + seizure model (astrocytes)","pmids":["36606511","36049541","35182379"],"confidence":"Medium","gaps":["Direct PKC phosphorylation sites on TRPV4 not biochemically mapped","Sequence of YAP activation relative to channel gating unresolved"]},{"year":2023,"claim":"Provided atomic-resolution mechanism: cryo-EM placed RhoA on the ankyrin-domain surface and localized agonist/antagonist action at the VSLD with defined gating transitions, while establishing the TRPV4-eNOS vasodilatory complex and endothelial mechanotransduction roles.","evidence":"Cryo-EM of TRPV4-RhoA and ligand-bound states; Co-IP/FRET/mutagenesis + endothelial KO (eNOS); endothelium-specific KO + RNA-seq + stiffness gels (cardiac hypertrophy)","pmids":["37353478","34822720","37702061"],"confidence":"High","gaps":["Structural basis of mechanical/osmotic gating not captured","eNOS-binding interface residues require independent validation"]},{"year":2024,"claim":"Refined the VSLD pharmacophore by resolving two antagonist binding modes and an associated symmetry transition, informing inhibitor design.","evidence":"Cryo-EM of two antagonist complexes with electrophysiology and MD simulation","pmids":["38659239"],"confidence":"High","gaps":["Functional relevance of symmetry transition in native cells untested","Selectivity over other TRPV channels not addressed"]},{"year":null,"claim":"The structural basis by which physical stimuli (osmotic swelling, heat, mechanical strain) are transduced into pore opening remains unresolved despite multiple ligand-bound structures.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of a mechanically/osmotically gated state","Role of membrane lipids and cytoskeleton in physiological gating not structurally defined","Mechanism distinguishing TRPV4 from PIEZO1 mechanotransduction unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[2,3,29]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,1,3]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,21]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[13,15]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,24]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[7]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[13,15]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,19,16]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,18,21]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,3]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[22,26,11]}],"complexes":["TRPV4-RhoA complex","TRPV4-eNOS complex","TRPV1-TRPV4 heteromeric channel"],"partners":["RHOA","NOS3","TMEM16F","TRPV1","CAV1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9HBA0","full_name":"Transient receptor potential cation channel subfamily V member 4","aliases":["Osm-9-like TRP channel 4","OTRPC4","Transient receptor potential protein 12","TRP12","Vanilloid receptor-like channel 2","Vanilloid receptor-like protein 2","VRL-2","Vanilloid receptor-related osmotically-activated channel","VR-OAC"],"length_aa":871,"mass_kda":98.3,"function":"Non-selective calcium permeant cation channel involved in osmotic sensitivity and mechanosensitivity (PubMed:16293632, PubMed:18695040, PubMed:18826956, PubMed:22526352, PubMed:23136043, PubMed:29899501). Activation by exposure to hypotonicity within the physiological range exhibits an outward rectification (PubMed:18695040, PubMed:18826956, PubMed:29899501). Also activated by heat, low pH, citrate and phorbol esters (PubMed:16293632, PubMed:18695040, PubMed:18826956, PubMed:20037586, PubMed:21964574, PubMed:25256292). Increase of intracellular Ca(2+) potentiates currents. Channel activity seems to be regulated by a calmodulin-dependent mechanism with a negative feedback mechanism (PubMed:12724311, PubMed:18826956). Promotes cell-cell junction formation in skin keratinocytes and plays an important role in the formation and/or maintenance of functional intercellular barriers (By similarity). Acts as a regulator of intracellular Ca(2+) in synoviocytes (PubMed:19759329). Plays an obligatory role as a molecular component in the nonselective cation channel activation induced by 4-alpha-phorbol 12,13-didecanoate and hypotonic stimulation in synoviocytes and also regulates production of IL-8 (PubMed:19759329). Together with PKD2, forms mechano- and thermosensitive channels in cilium (PubMed:18695040). Negatively regulates expression of PPARGC1A, UCP1, oxidative metabolism and respiration in adipocytes (By similarity). Regulates expression of chemokines and cytokines related to pro-inflammatory pathway in adipocytes (By similarity). Together with AQP5, controls regulatory volume decrease in salivary epithelial cells (By similarity). Required for normal development and maintenance of bone and cartilage (PubMed:26249260). In its inactive state, may sequester DDX3X at the plasma membrane. When activated, the interaction between both proteins is affected and DDX3X relocalizes to the nucleus (PubMed:29899501). In neurons of the central nervous system, could play a role in triggering voluntary water intake in response to increased sodium concentration in body fluid (By similarity) Non-selective calcium permeant cation channel involved in osmotic sensitivity and mechanosensitivity. Activation by exposure to hypotonicity within the physiological range exhibits an outward rectification. Also activated by phorbol esters. Has the same channel activity as isoform 1, and is activated by the same stimuli Non-selective calcium permeant cation channel involved in osmotic sensitivity and mechanosensitivity. Activation by exposure to hypotonicity within the physiological range exhibits an outward rectification. Also activated by phorbol esters. Has the same channel activity as isoform 1, and is activated by the same stimuli Lacks channel activity, due to impaired oligomerization and intracellular retention Lacks channel activity, due to impaired oligomerization and intracellular retention Lacks channel activity, due to impaired oligomerization and intracellular retention (Microbial infection) Facilitates hepatitis C virus (HCV) replication, possibly through its action on DDX3X (Microbial infection) Facilitates Dengue virus (DENV) replication, possibly through its action on DDX3X (Microbial infection) Facilitates Zika virus (ZIKV) replication, possibly through its action on DDX3X","subcellular_location":"Endoplasmic reticulum","url":"https://www.uniprot.org/uniprotkb/Q9HBA0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TRPV4","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TRPV4","total_profiled":1310},"omim":[{"mim_id":"620447","title":"MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 3; MLC3","url":"https://www.omim.org/entry/620447"},{"mim_id":"617383","title":"AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY, 2; ANFH2","url":"https://www.omim.org/entry/617383"},{"mim_id":"613508","title":"SODIUM SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1; SSQTL1","url":"https://www.omim.org/entry/613508"},{"mim_id":"611642","title":"HEPATOCYTE CELL ADHESION MOLECULE; HEPACAM","url":"https://www.omim.org/entry/611642"},{"mim_id":"608805","title":"AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY, 1; ANFH1","url":"https://www.omim.org/entry/608805"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"choroid plexus","ntpm":69.8}],"url":"https://www.proteinatlas.org/search/TRPV4"},"hgnc":{"alias_symbol":["OTRPC4","TRP12","VROAC","VRL-2","VR-OAC","CMT2C"],"prev_symbol":[]},"alphafold":{"accession":"Q9HBA0","domains":[{"cath_id":"1.20.120","chopping":"457-598","consensus_level":"medium","plddt":83.4788,"start":457,"end":598}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HBA0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HBA0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HBA0-F1-predicted_aligned_error_v6.png","plddt_mean":71.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TRPV4","jax_strain_url":"https://www.jax.org/strain/search?query=TRPV4"},"sequence":{"accession":"Q9HBA0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9HBA0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9HBA0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HBA0"}},"corpus_meta":[{"pmid":"11827975","id":"PMC_11827975","title":"Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11827975","citation_count":485,"is_preprint":false},{"pmid":"14707014","id":"PMC_14707014","title":"TRPV4 calcium entry channel: a paradigm for gating diversity.","date":"2004","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/14707014","citation_count":373,"is_preprint":false},{"pmid":"27252279","id":"PMC_27252279","title":"TRPV4: Molecular Conductor of a Diverse Orchestra.","date":"2016","source":"Physiological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27252279","citation_count":328,"is_preprint":false},{"pmid":"12093812","id":"PMC_12093812","title":"Molecular determinants of permeation through the cation channel TRPV4.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12093812","citation_count":262,"is_preprint":false},{"pmid":"11094154","id":"PMC_11094154","title":"Trp12, a novel Trp related protein from kidney.","date":"2000","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11094154","citation_count":248,"is_preprint":false},{"pmid":"23306656","id":"PMC_23306656","title":"The puzzle of TRPV4 channelopathies.","date":"2013","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/23306656","citation_count":246,"is_preprint":false},{"pmid":"33629929","id":"PMC_33629929","title":"Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/33629929","citation_count":182,"is_preprint":false},{"pmid":"11160995","id":"PMC_11160995","title":"Identification and characterization of a novel human vanilloid receptor-like protein, VRL-2.","date":"2001","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11160995","citation_count":181,"is_preprint":false},{"pmid":"23107877","id":"PMC_23107877","title":"TRPV4 and the regulation of vascular tone.","date":"2013","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23107877","citation_count":142,"is_preprint":false},{"pmid":"24756711","id":"PMC_24756711","title":"The TRPV4 channel.","date":"2014","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24756711","citation_count":131,"is_preprint":false},{"pmid":"12715179","id":"PMC_12715179","title":"The TRPV4 channel: structure-function relationship and promiscuous gating behaviour.","date":"2003","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12715179","citation_count":125,"is_preprint":false},{"pmid":"21671873","id":"PMC_21671873","title":"TRPV4 agonists and antagonists.","date":"2011","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21671873","citation_count":118,"is_preprint":false},{"pmid":"27291497","id":"PMC_27291497","title":"TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27291497","citation_count":111,"is_preprint":false},{"pmid":"26763435","id":"PMC_26763435","title":"Involvement of TRPV4 in Serotonin-Evoked Scratching.","date":"2016","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26763435","citation_count":110,"is_preprint":false},{"pmid":"11713648","id":"PMC_11713648","title":"Differential activation of the volume-sensitive cation channel TRP12 (OTRPC4) and volume-regulated anion currents in HEK-293 cells.","date":"2001","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11713648","citation_count":110,"is_preprint":false},{"pmid":"32210976","id":"PMC_32210976","title":"TRPV4-A Missing Link Between Mechanosensation and Immunity.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32210976","citation_count":100,"is_preprint":false},{"pmid":"33230171","id":"PMC_33230171","title":"Calcium and TRPV4 promote metastasis by regulating cytoskeleton through the RhoA/ROCK1 pathway in endometrial cancer.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33230171","citation_count":100,"is_preprint":false},{"pmid":"32481620","id":"PMC_32481620","title":"TRPV4: A Physio and Pathophysiologically Significant Ion Channel.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32481620","citation_count":98,"is_preprint":false},{"pmid":"36701202","id":"PMC_36701202","title":"A TRPV4-dependent neuroimmune axis in the spinal cord promotes neuropathic pain.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36701202","citation_count":85,"is_preprint":false},{"pmid":"17217058","id":"PMC_17217058","title":"TRPV4.","date":"2007","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17217058","citation_count":84,"is_preprint":false},{"pmid":"25519495","id":"PMC_25519495","title":"TRPV4 as a therapeutic target for joint diseases.","date":"2014","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25519495","citation_count":75,"is_preprint":false},{"pmid":"30728775","id":"PMC_30728775","title":"The TRPV4 Agonist GSK1016790A Regulates the Membrane Expression of TRPV4 Channels.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30728775","citation_count":75,"is_preprint":false},{"pmid":"22791502","id":"PMC_22791502","title":"TRPV4-associated skeletal dysplasias.","date":"2012","source":"American journal of medical genetics. Part C, Seminars in medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22791502","citation_count":72,"is_preprint":false},{"pmid":"31645630","id":"PMC_31645630","title":"Role of macrophage TRPV4 in inflammation.","date":"2019","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31645630","citation_count":72,"is_preprint":false},{"pmid":"34663597","id":"PMC_34663597","title":"Mechanosensitive TRPV4 is required for crystal-induced inflammation.","date":"2021","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34663597","citation_count":71,"is_preprint":false},{"pmid":"19076362","id":"PMC_19076362","title":"Molecular mechanisms of TRPV4-mediated neural signaling.","date":"2008","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19076362","citation_count":71,"is_preprint":false},{"pmid":"27425399","id":"PMC_27425399","title":"Modulation of TRPV4 by diverse mechanisms.","date":"2016","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27425399","citation_count":69,"is_preprint":false},{"pmid":"35093118","id":"PMC_35093118","title":"TRPV4 contributes to ER stress and inflammation: implications for Parkinson's disease.","date":"2022","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/35093118","citation_count":64,"is_preprint":false},{"pmid":"25342095","id":"PMC_25342095","title":"TRPV4: physiological role and therapeutic potential in respiratory diseases.","date":"2014","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25342095","citation_count":63,"is_preprint":false},{"pmid":"32402646","id":"PMC_32402646","title":"Endothelial TRPV4 channels and vasodilator reactivity.","date":"2020","source":"Current topics in membranes","url":"https://pubmed.ncbi.nlm.nih.gov/32402646","citation_count":60,"is_preprint":false},{"pmid":"20676052","id":"PMC_20676052","title":"TRPV4-mediated channelopathies.","date":"2010","source":"Channels (Austin, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/20676052","citation_count":57,"is_preprint":false},{"pmid":"37353478","id":"PMC_37353478","title":"Structure of human TRPV4 in complex with GTPase RhoA.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37353478","citation_count":57,"is_preprint":false},{"pmid":"33300268","id":"PMC_33300268","title":"TRPV4 integrates matrix mechanosensing with Ca2+ signaling to regulate extracellular matrix remodeling.","date":"2020","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/33300268","citation_count":56,"is_preprint":false},{"pmid":"24440740","id":"PMC_24440740","title":"TRPV4: new therapeutic target for inflammatory bowel diseases.","date":"2014","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24440740","citation_count":53,"is_preprint":false},{"pmid":"34710431","id":"PMC_34710431","title":"Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension.","date":"2021","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/34710431","citation_count":50,"is_preprint":false},{"pmid":"35207158","id":"PMC_35207158","title":"TRPV4 and PIEZO Channels Mediate the Mechanosensing of Chondrocytes to the Biomechanical Microenvironment.","date":"2022","source":"Membranes","url":"https://pubmed.ncbi.nlm.nih.gov/35207158","citation_count":49,"is_preprint":false},{"pmid":"15952033","id":"PMC_15952033","title":"TRPV4 as osmosensor: a transgenic approach.","date":"2005","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15952033","citation_count":48,"is_preprint":false},{"pmid":"19701771","id":"PMC_19701771","title":"The progesterone receptor regulates the expression of TRPV4 channel.","date":"2009","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19701771","citation_count":48,"is_preprint":false},{"pmid":"15988590","id":"PMC_15988590","title":"TRPV4 and the mammalian kidney.","date":"2005","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15988590","citation_count":46,"is_preprint":false},{"pmid":"33664271","id":"PMC_33664271","title":"Neuropathy-causing TRPV4 mutations disrupt TRPV4-RhoA interactions and impair neurite extension.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33664271","citation_count":46,"is_preprint":false},{"pmid":"34989943","id":"PMC_34989943","title":"A novel antagonist of TRPM2 and TRPV4 channels: Carvacrol.","date":"2022","source":"Metabolic brain disease","url":"https://pubmed.ncbi.nlm.nih.gov/34989943","citation_count":45,"is_preprint":false},{"pmid":"33624376","id":"PMC_33624376","title":"TRPV4 channels mediate the mechanoresponse in retinal microglia.","date":"2021","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/33624376","citation_count":44,"is_preprint":false},{"pmid":"20505684","id":"PMC_20505684","title":"TRPV4-pathy, a novel channelopathy affecting diverse systems.","date":"2010","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20505684","citation_count":43,"is_preprint":false},{"pmid":"33888579","id":"PMC_33888579","title":"Thermosensitive TRPV4 channels mediate temperature-dependent microglia movement.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33888579","citation_count":43,"is_preprint":false},{"pmid":"38334061","id":"PMC_38334061","title":"Electroacupuncture ameliorates neuroinflammation by inhibiting TRPV4 channel in ischemic stroke.","date":"2024","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38334061","citation_count":39,"is_preprint":false},{"pmid":"32979394","id":"PMC_32979394","title":"The role of TRPV4 channels in ocular function and pathologies.","date":"2020","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/32979394","citation_count":39,"is_preprint":false},{"pmid":"32676078","id":"PMC_32676078","title":"The Role of TRPV4 in Regulating Innate Immune Cell Function in Lung Inflammation.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32676078","citation_count":39,"is_preprint":false},{"pmid":"23207579","id":"PMC_23207579","title":"Novel insights into TRPV4 function in the kidney.","date":"2012","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23207579","citation_count":39,"is_preprint":false},{"pmid":"32843668","id":"PMC_32843668","title":"TRPV4 activates the Cdc42/N-wasp pathway to promote glioblastoma invasion by altering cellular protrusions.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32843668","citation_count":39,"is_preprint":false},{"pmid":"29126921","id":"PMC_29126921","title":"The role of TRPV4 in fibrosis.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29126921","citation_count":38,"is_preprint":false},{"pmid":"29582401","id":"PMC_29582401","title":"TRPV4: a Sensor for Homeostasis and Pathological Events in the CNS.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29582401","citation_count":38,"is_preprint":false},{"pmid":"31896814","id":"PMC_31896814","title":"TRPV4 activation by thermal and mechanical stimuli in disease progression.","date":"2020","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31896814","citation_count":38,"is_preprint":false},{"pmid":"33724130","id":"PMC_33724130","title":"TRPV4 antagonists: a patent review (2015-2020).","date":"2021","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/33724130","citation_count":37,"is_preprint":false},{"pmid":"29928875","id":"PMC_29928875","title":"TRPV4 promotes the migration and invasion of glioma cells via AKT/Rac1 signaling.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29928875","citation_count":37,"is_preprint":false},{"pmid":"35670667","id":"PMC_35670667","title":"Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35670667","citation_count":35,"is_preprint":false},{"pmid":"31369032","id":"PMC_31369032","title":"Involvement of TRPV1 and TRPV4 Channels in Retinal Angiogenesis.","date":"2019","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/31369032","citation_count":35,"is_preprint":false},{"pmid":"35126384","id":"PMC_35126384","title":"Diverse Roles of TRPV4 in Macrophages: A Need for Unbiased Profiling.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35126384","citation_count":34,"is_preprint":false},{"pmid":"30328352","id":"PMC_30328352","title":"TRPM3/TRPV4 regulates Ca2+-mediated RANKL/NFATc1 expression in osteoblasts.","date":"2018","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30328352","citation_count":34,"is_preprint":false},{"pmid":"33537292","id":"PMC_33537292","title":"Modulating the Mechanical Activation of TRPV4 at the Cell-Substrate Interface.","date":"2021","source":"Frontiers in bioengineering and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/33537292","citation_count":34,"is_preprint":false},{"pmid":"27506578","id":"PMC_27506578","title":"TRPV4 ion channel as important cell sensors.","date":"2016","source":"Journal of anesthesia","url":"https://pubmed.ncbi.nlm.nih.gov/27506578","citation_count":33,"is_preprint":false},{"pmid":"36670886","id":"PMC_36670886","title":"TRPV4 Role in Neuropathic Pain Mechanisms in Rodents.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36670886","citation_count":33,"is_preprint":false},{"pmid":"33119551","id":"PMC_33119551","title":"TRPV4 blockade suppresses atrial fibrillation in sterile pericarditis rats.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33119551","citation_count":33,"is_preprint":false},{"pmid":"36509176","id":"PMC_36509176","title":"Sensory Neuron-TRPV4 Modulates Temporomandibular Disorder Pain Via CGRP in Mice.","date":"2022","source":"The journal of pain","url":"https://pubmed.ncbi.nlm.nih.gov/36509176","citation_count":31,"is_preprint":false},{"pmid":"22617546","id":"PMC_22617546","title":"TRPV4 axonal neuropathy spectrum disorder.","date":"2012","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/22617546","citation_count":31,"is_preprint":false},{"pmid":"29601335","id":"PMC_29601335","title":"Mechanosensitive Ion Channels: TRPV4 and P2X7 in Disseminating Cancer Cells.","date":"2018","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/29601335","citation_count":29,"is_preprint":false},{"pmid":"36696489","id":"PMC_36696489","title":"Mechanoregulatory role of TRPV4 in prenatal skeletal development.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36696489","citation_count":29,"is_preprint":false},{"pmid":"38959010","id":"PMC_38959010","title":"The chondrocyte \"mechanome\": Activation of the mechanosensitive ion channels TRPV4 and PIEZO1 drives unique transcriptional signatures.","date":"2024","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/38959010","citation_count":28,"is_preprint":false},{"pmid":"37702061","id":"PMC_37702061","title":"Deletion of Endothelial TRPV4 Protects Heart From Pressure Overload-Induced Hypertrophy.","date":"2023","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/37702061","citation_count":28,"is_preprint":false},{"pmid":"34822720","id":"PMC_34822720","title":"Endothelial TRPV4-eNOS coupling as a vital therapy target for treatment of hypertension.","date":"2022","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34822720","citation_count":28,"is_preprint":false},{"pmid":"33917551","id":"PMC_33917551","title":"Ca2+ Signaling by TRPV4 Channels in Respiratory Function and Disease.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33917551","citation_count":27,"is_preprint":false},{"pmid":"35297520","id":"PMC_35297520","title":"TRPV4: A trigger of pathological RhoA activation in neurological disease.","date":"2022","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35297520","citation_count":27,"is_preprint":false},{"pmid":"33052604","id":"PMC_33052604","title":"Emerging roles of the TRPV4 channel in bladder physiology and dysfunction.","date":"2020","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33052604","citation_count":27,"is_preprint":false},{"pmid":"34616399","id":"PMC_34616399","title":"TRPing on Cell Swelling - TRPV4 Senses It.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34616399","citation_count":26,"is_preprint":false},{"pmid":"28028935","id":"PMC_28028935","title":"Renoprotection: focus on TRPV1, TRPV4, TRPC6 and TRPM2.","date":"2016","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28028935","citation_count":25,"is_preprint":false},{"pmid":"35182379","id":"PMC_35182379","title":"Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4) Mitigates Seizures.","date":"2022","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35182379","citation_count":25,"is_preprint":false},{"pmid":"28456852","id":"PMC_28456852","title":"Fluid-induced lung injury-role of TRPV4 channels.","date":"2017","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28456852","citation_count":25,"is_preprint":false},{"pmid":"34766332","id":"PMC_34766332","title":"Glucosylsphingosine evokes pruritus via activation of 5-HT2A receptor and TRPV4 in sensory neurons.","date":"2022","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34766332","citation_count":25,"is_preprint":false},{"pmid":"37371124","id":"PMC_37371124","title":"Pathophysiological Roles of the TRPV4 Channel in the Heart.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37371124","citation_count":24,"is_preprint":false},{"pmid":"33971061","id":"PMC_33971061","title":"Role of TRPV4 channel in vasodilation and neovascularization.","date":"2021","source":"Microcirculation (New York, N.Y. : 1994)","url":"https://pubmed.ncbi.nlm.nih.gov/33971061","citation_count":24,"is_preprint":false},{"pmid":"32524421","id":"PMC_32524421","title":"Channels that Cooperate with TRPV4 in the Brain.","date":"2020","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/32524421","citation_count":24,"is_preprint":false},{"pmid":"37377733","id":"PMC_37377733","title":"TRPV4 regulates osteoblast differentiation and mitochondrial function that are relevant for channelopathy.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/37377733","citation_count":24,"is_preprint":false},{"pmid":"37108263","id":"PMC_37108263","title":"Astrocytic TRPV4 Channels and Their Role in Brain Ischemia.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37108263","citation_count":23,"is_preprint":false},{"pmid":"32871457","id":"PMC_32871457","title":"Modulating TRPV4 channels with paclitaxel and lithium.","date":"2020","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/32871457","citation_count":23,"is_preprint":false},{"pmid":"38256251","id":"PMC_38256251","title":"The Multifaceted Functions of TRPV4 and Calcium Oscillations in Tissue Repair.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38256251","citation_count":23,"is_preprint":false},{"pmid":"35456964","id":"PMC_35456964","title":"Activation of TRPV4 Induces Exocytosis and Ferroptosis in Human Melanoma Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35456964","citation_count":22,"is_preprint":false},{"pmid":"34299208","id":"PMC_34299208","title":"Emerging Role of Transient Receptor Potential Vanilloid 4 (TRPV4) Ion Channel in Acute and Chronic Itch.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34299208","citation_count":22,"is_preprint":false},{"pmid":"36606511","id":"PMC_36606511","title":"The CaSR/TRPV4 coupling mediates pro-inflammatory macrophage function.","date":"2023","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36606511","citation_count":21,"is_preprint":false},{"pmid":"34605007","id":"PMC_34605007","title":"Mitochondria regulate TRPV4-mediated release of ATP.","date":"2021","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34605007","citation_count":20,"is_preprint":false},{"pmid":"30848206","id":"PMC_30848206","title":"Physiological and Pathological Role of TRPV1, TRPV2 and TRPV4 Channels in Heart.","date":"2019","source":"Current cardiology reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30848206","citation_count":20,"is_preprint":false},{"pmid":"34611585","id":"PMC_34611585","title":"TRPV4 mediates cell damage induced by hyperphysiological compression and regulates COX2/PGE2 in intervertebral discs.","date":"2021","source":"JOR spine","url":"https://pubmed.ncbi.nlm.nih.gov/34611585","citation_count":20,"is_preprint":false},{"pmid":"33805168","id":"PMC_33805168","title":"Regulation of TGFβ Signalling by TRPV4 in Chondrocytes.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33805168","citation_count":19,"is_preprint":false},{"pmid":"38659239","id":"PMC_38659239","title":"Structural Pharmacology of TRPV4 Antagonists.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38659239","citation_count":18,"is_preprint":false},{"pmid":"28528666","id":"PMC_28528666","title":"Role of Nonneuronal TRPV4 Signaling in Inflammatory Processes.","date":"2017","source":"Advances in pharmacology (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/28528666","citation_count":18,"is_preprint":false},{"pmid":"37880726","id":"PMC_37880726","title":"Cell-specific NFIA upregulation promotes epileptogenesis by TRPV4-mediated astrocyte reactivity.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37880726","citation_count":17,"is_preprint":false},{"pmid":"36773739","id":"PMC_36773739","title":"TRPV4 channels promote vascular permeability in retinal vascular disease.","date":"2023","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/36773739","citation_count":16,"is_preprint":false},{"pmid":"37178575","id":"PMC_37178575","title":"Transient Receptor Potential Vanilloid (TRPV4) channel inhibition: A novel promising approach for the treatment of lung diseases.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37178575","citation_count":16,"is_preprint":false},{"pmid":"36210150","id":"PMC_36210150","title":"Role of TRPV4 in skeletal function and its mutant-mediated skeletal disorders.","date":"2022","source":"Current topics in membranes","url":"https://pubmed.ncbi.nlm.nih.gov/36210150","citation_count":16,"is_preprint":false},{"pmid":"36049541","id":"PMC_36049541","title":"miRNA-203b-3p Induces Acute and Chronic Pruritus through 5-HTR2B and TRPV4.","date":"2022","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/36049541","citation_count":15,"is_preprint":false},{"pmid":"36499486","id":"PMC_36499486","title":"TRPV4 Promotes Metastasis in Melanoma by Regulating Cell Motility through Cytoskeletal Rearrangement.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36499486","citation_count":15,"is_preprint":false},{"pmid":"36210147","id":"PMC_36210147","title":"The role of TRPV4 channels in cutaneous epithelia.","date":"2022","source":"Current topics in membranes","url":"https://pubmed.ncbi.nlm.nih.gov/36210147","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45970,"output_tokens":8104,"usd":0.129735,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17732,"output_tokens":4770,"usd":0.103955,"stage2_stop_reason":"end_turn"},"total_usd":0.23369,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"4α-Phorbol 12,13-didecanoate (4α-PDD) directly gates TRPV4 as an agonist, activating an outwardly rectifying, Ca2+-permeable cation channel (PCa/PNa ≈ 5.8) in cells expressing hVRL-2/mTRP12; this activation is independent of protein kinase C and is modulated by intracellular Ca2+ (inhibitory IC50 ≈ 406 nM). Ruthenium Red blocks inward currents in a voltage-dependent manner.\",\n      \"method\": \"Whole-cell patch-clamp and Ca2+ imaging in stably/transiently transfected 1321N1 and HEK-293 cells; pharmacological PKC dissection; native aortic endothelial cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct electrophysiological reconstitution in heterologous system with pharmacological dissection, replicated across two cell lines and native tissue\",\n      \"pmids\": [\"11827975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Asp672 and Asp682 in the pore region are critical determinants of Ca2+ permeability and outward rectification; Met680 at the putative selectivity filter is essential for current amplitude and Ca2+ permeation; Asp682 (but not Asp672) controls Ruthenium Red affinity; Lys675 (the only positive pore residue) is dispensable for pore function.\",\n      \"method\": \"Site-directed mutagenesis combined with whole-cell patch-clamp and ion substitution reversal-potential measurements in transfected HEK-293 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structure-function reconstitution with systematic mutagenesis of multiple residues, multiple orthogonal readouts in one rigorous study\",\n      \"pmids\": [\"12093812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Trp12 (murine TRPV4 ortholog) forms a Ca2+-permeable channel: heterologous expression elevates basal cytosolic Ca2+ and confers a further increase upon hypoosmotic stimulation, establishing osmosensory gating of this channel.\",\n      \"method\": \"Heterologous expression in transfected cells with cytosolic Ca2+ measurements under hypoosmotic challenge\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional expression in heterologous system with osmotic challenge, single lab, two readouts (basal Ca2+ elevation and hypotonicity response)\",\n      \"pmids\": [\"11094154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Heterologous expression of TRP12/OTRPC4 (TRPV4) in HEK-293 cells produces a swelling-activated cation current with Eisenman-IV permeability sequence (PK>PCs>PNa>PLi); overexpression simultaneously down-regulates the endogenous volume-regulated anion channel (VRAC). Unlike VRAC, TRP12 is not activated by reduced intracellular ionic strength or intracellular GTPγS at constant volume.\",\n      \"method\": \"Whole-cell patch-clamp in transfected HEK-293 cells with hypotonic swelling; ionic substitution; pharmacological and ionic-strength manipulations\",\n      \"journal\": \"Pflugers Archiv : European journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous electrophysiological reconstitution with multiple negative controls; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"11713648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRPV4 physically interacts with RhoA via the TRPV4 N-terminal ankyrin repeat domain; this interaction suppresses TRPV4 channel activity and inhibits RhoA activation, thereby promoting neurite extension. Neuropathy-causing (but not skeletal dysplasia) mutations in the N-terminal domain disrupt TRPV4-RhoA binding, impairing cytoskeletal outgrowth. RhoA inhibition rescues neurite length both in vitro and in a Drosophila model of TRPV4 neuropathy.\",\n      \"method\": \"Unbiased protein interaction screen, Co-IP, functional channel recordings, neurite-outgrowth assays with disease-associated point mutants, Drosophila in vivo rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, functional channel assay, mutagenesis, two model systems (mammalian cells and Drosophila); multiple orthogonal methods across one study\",\n      \"pmids\": [\"33664271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structure of human TRPV4 in complex with GTPase RhoA shows RhoA contacts the membrane-facing surface of the TRPV4 ankyrin repeat domains. The agonist 4α-PDD and inhibitor HC-067047 bind at the base of the S1-S4 bundle (voltage-sensing-like domain): 4α-PDD binding leads to pore opening, whereas HC-067047 stabilizes a closed state involving a π-to-α helix transition in pore-forming helix S6.\",\n      \"method\": \"Cryo-EM structure determination with functional validation; binding-site mutagenesis context inferred from disease-mutation mapping at the RhoA interface\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure with ligand-bound states and functional mechanistic interpretation; disease-mutation mapping provides orthogonal validation\",\n      \"pmids\": [\"37353478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of human TRPV4 with two potent antagonists reveal both ligands bind the voltage-sensing-like domain (VSLD) and stabilize closed channel states; one antagonist occupies the canonical VSLD pocket and the other a novel extended VSLD pocket. Antagonist binding induces a fourfold-to-twofold symmetry transition in the channel.\",\n      \"method\": \"Cryo-EM structure determination complemented with functional electrophysiology and molecular dynamics simulation\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM with two distinct antagonist complexes, functional data, and MD simulation in one study\",\n      \"pmids\": [\"38659239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TRPV4 stimulation with GSK1016790A decreases plasma-membrane TRPV4 density within ~20 min through translocation to recycling endosomes via two modes of vesicular fusion; surface density is regulated by intracellular Ca2+ release and controlled by a PI3K/PKC/RhoA signaling pathway.\",\n      \"method\": \"Single-molecule imaging, live-cell fluorescence, pharmacological inhibition of PI3K, PKC, RhoA in transfected cells\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single-molecule trafficking analysis plus pharmacological pathway dissection; single lab, multiple imaging methods\",\n      \"pmids\": [\"30728775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Progesterone, acting through the progesterone receptor (PR), transcriptionally represses TRPV4 expression; PR activation reduces TRPV4 mRNA, protein, and 4α-PDD-evoked currents/Ca2+ signals in airway and mammary epithelial cells. The effect is reversed by the PR antagonist RU-486 or siRNA knockdown of both PRA and PRB isoforms. PR co-expression suppresses TRPV4 promoter-driven reporter activity.\",\n      \"method\": \"RT-PCR, Western blot, whole-cell patch-clamp, Ca2+ imaging, siRNA knockdown, promoter-luciferase reporter assays\",\n      \"journal\": \"Pflugers Archiv : European journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (mRNA, protein, electrophysiology, Ca2+ imaging, reporter assay, siRNA), single lab\",\n      \"pmids\": [\"19701771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRPV4-mediated Ca2+ influx functionally couples to the Ca2+-activated phospholipid scramblase TMEM16F within Ca2+ microdomains in human trophoblasts, driving TMEM16F activation and subsequent trophoblast syncytialization. Pharmacological inhibition or gene silencing of TRPV4 reduces TMEM16F activation and cell fusion.\",\n      \"method\": \"Patch-clamp electrophysiology, pharmacological agonist/antagonist, siRNA knockdown, cell fusion assays in human trophoblast cell line\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal pharmacological and genetic (siRNA) evidence with electrophysiological Ca2+-microdomain characterization; multiple orthogonal methods in one study\",\n      \"pmids\": [\"35670667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Depolarized mitochondria switch TRPV4-evoked Ca2+ signaling from IP3R-dependent Ca2+-induced Ca2+ release to mitochondria-independent Ca2+ waves mediated by ATP release through pannexin channels, which then activate purinergic receptors to trigger IP3 store release. This identifies mitochondria as regulators of TRPV4-Ca2+ signal mode in endothelial cells.\",\n      \"method\": \"Ca2+ imaging (Cal520) in rat mesenteric artery endothelium; pharmacological dissection with CCCP, rotenone, oligomycin, HC067047, U73122, caffeine, suramin, apyrase, probenecid\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — native tissue preparation with systematic pharmacological dissection; single lab, multiple mechanistic probes\",\n      \"pmids\": [\"34605007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Microglial TRPV4 mediates microglial activation and proliferation after nerve injury, and promotes excitatory spinal neuron plasticity through release of lipocalin-2, linking peripheral nerve injury to central sensitization and neuropathic pain.\",\n      \"method\": \"Genetic ablation (Trpv4 KO) and pharmacological blockade in spared nerve injury mouse model; lipocalin-2 measurement; electrophysiological and morphological assessment of spinal neurons\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus pharmacological inhibition with defined cellular phenotype and identified downstream mediator (lipocalin-2); single lab\",\n      \"pmids\": [\"36701202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRPV4 mediates NLRP3 inflammasome activation induced by crystalline (but not non-crystalline) NLRP3 activators in synovial macrophages, driving IL-1β production and crystal-induced gouty arthritis; TRPV4 expression is functionally confirmed in synovial macrophages and upregulated by MSU crystal stimulation.\",\n      \"method\": \"Whole-cell patch-clamp, live-cell Ca2+ imaging, TRPV4 KO and pharmacological inhibition, in vitro NLRP3 inflammasome assays, in vivo gout models\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — electrophysiology, genetic deletion, pharmacological inhibition, in vitro and in vivo models, specificity control (non-crystalline activators unaffected); multiple orthogonal approaches\",\n      \"pmids\": [\"34663597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRPV4 activates the Cdc42/N-WASP pathway to regulate formation of invadopodia and filopodia at cellular protrusions, promoting glioblastoma cell migration and invasion in vitro and tumor growth in vivo. TRPV4 co-localizes and interacts with F-actin at protrusions.\",\n      \"method\": \"Co-IP/co-localization with F-actin, TRPV4 siRNA knockdown, pharmacological agonist/antagonist, invasion assays, subcutaneous and intracranial mouse xenograft models\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, KD and pharmacological approaches with in vitro and in vivo readouts; single lab\",\n      \"pmids\": [\"32843668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TRPV4 activation promotes glioma cell migration and invasion via AKT phosphorylation leading to Rac1 activation; pharmacological TRPV4 agonism enhances and antagonism suppresses this pathway.\",\n      \"method\": \"Pharmacological agonist (GSK1016790A) and antagonist (HC-067047), Western blot for AKT phosphorylation and Rac1 activation, migration/invasion assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological gain- and loss-of-function with pathway readouts; single lab, single channel activation approach\",\n      \"pmids\": [\"29928875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRPV4 is required for breast cancer cell invasion and transendothelial migration (but not proliferation); TRPV4 overexpression promotes cell softness, blebbing, and actin cortex reorganization, reducing cell rigidity.\",\n      \"method\": \"siRNA knockdown, overexpression, transendothelial migration assays, mouse xenograft, atomic force microscopy/cell stiffness measurements, live imaging\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD and OE with multiple phenotypic readouts including biomechanical measurements; single lab\",\n      \"pmids\": [\"27291497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRPV4 calcium influx activates the RhoA/ROCK1 pathway leading to LIMK/cofilin activation, which regulates F-actin and paxillin (PXN) levels, driving endometrial cancer cell migration and invasion.\",\n      \"method\": \"Proteomic/bioinformatics analysis, overexpression and knockdown, pharmacological Ca2+ manipulation, Western blot for RhoA/ROCK1/LIMK/cofilin/paxillin, migration assays, in vivo xenograft\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway dissection with KD/OE and in vivo confirmation; single lab, multiple biochemical readouts\",\n      \"pmids\": [\"33230171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TRPV4 activity in astrocytes promotes neuroinflammation through a TRPV4/Ca2+/YAP/STAT3 signaling pathway; YAP siRNA knockdown blocks 4-AP-induced astrocyte reactivity and cytokine release downstream of TRPV4.\",\n      \"method\": \"siRNA knockdown of TRPV4 and YAP, pharmacological TRPV4 inhibition, Ca2+ imaging, cytokine ELISA, in vivo mouse seizure model and human epileptic tissue analysis\",\n      \"journal\": \"Neurotherapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (siRNA) and pharmacological approaches in vitro and in vivo with defined pathway (TRPV4/Ca2+/YAP/STAT3); single lab\",\n      \"pmids\": [\"35182379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Calcium-sensing receptor (CaSR) couples to TRPV4 channels in macrophages via PLA2/cytochrome P450 and PLC/PKC pathways; CaSR activation drives extracellular Ca2+ entry predominantly through TRPV4, and this CaSR-TRPV4 coupling promotes M1 macrophage polarization and cytokine (IL-1β, TNFα) production.\",\n      \"method\": \"Pharmacological inhibition of CaSR and TRPV4, TRPV4 KO mice peritoneal macrophages, digital Ca2+ imaging, immunofluorescence, ELISA, Western blot, qPCR\",\n      \"journal\": \"Acta physiologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mice plus pharmacological dissection with pathway intermediates identified; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36606511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Endothelial TRPV4 forms a functional complex with eNOS (endothelial nitric oxide synthase); TRPV4-eNOS interaction promotes vasodilation and regulates blood pressure. This interaction is impaired during hypertension, and a small molecule (JNc-463) designed to enhance TRPV4-eNOS interaction restores vasodilation and exerts antihypertensive effects in mice.\",\n      \"method\": \"Co-immunoprecipitation, immuno-FRET, site-directed mutagenesis to map binding site, endothelium-specific TRPV4 KO mice, single-cell RNA-seq, molecular docking and in vivo pharmacology\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP, FRET, mutagenesis-mapped binding site, endothelium-specific KO, and pharmacological rescue; multiple orthogonal methods in one study\",\n      \"pmids\": [\"34822720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Retinal microglial TRPV4 activation (by agonist GSK1016790A or hypotonicity) requires intermediary activation of phospholipase A2 (PLA2), cytochrome P450, and epoxyeicosatrienoic acid (EET) production; TRPV4 activation in microglia triggers Ca2+ elevation, outwardly rectifying cation current, and retraction of higher-order processes.\",\n      \"method\": \"Ca2+ imaging, whole-cell patch-clamp, pharmacological inhibition of PLA2/CYP450/EET pathway and TRPV4 antagonist HC067047 in dissociated and intact microglia\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — electrophysiology and Ca2+ imaging with pharmacological pathway dissection in native retinal microglia; single lab\",\n      \"pmids\": [\"33624376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Thermosensitive TRPV4 channels mediate temperature-dependent microglial movement within the physiological body temperature range (>34°C activation threshold in brain); TRPV4 deletion abolishes temperature-dependent microglial motility both in vitro and in vivo.\",\n      \"method\": \"TRPV4 KO mice, live two-photon imaging of microglia in vivo, in vitro motility assays across temperature range, pharmacological TRPV4 inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO validated in vitro and in vivo with two-photon imaging, pharmacological confirmation; multiple orthogonal approaches\",\n      \"pmids\": [\"33888579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRPV4 mediates serotonin (5-HT)-evoked itch: TRPV4 KO mice show significantly fewer 5-HT-induced (but not histamine- or SLIGRL-induced) scratching bouts; ~90% of 5-HT-sensitive DRG neurons are TRPV4-immunoreactive; TRPV4 antagonism suppresses 5-HT-evoked Ca2+ responses in DRG neurons.\",\n      \"method\": \"TRPV4 KO mice behavioral assay, pharmacological antagonist in vivo, Ca2+ imaging in primary DRG neurons, immunostaining\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mice plus pharmacological antagonism with behavioral and cellular readouts; specificity confirmed by negative controls (histamine, SLIGRL unaffected)\",\n      \"pmids\": [\"26763435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Hypo-osmotic stress increases RANKL and NFATc1 expression in osteoblasts via Ca2+ influx through both TRPM3 and TRPV4; genetic knockdown of Trpv4 (and Trpm3) reduces hypotonic-stress-induced Ca2+ rise and RANKL/NFATc1 expression.\",\n      \"method\": \"Pharmacological agonists/antagonists of TRPM3 and TRPV4, siRNA/shRNA knockdown, Ca2+ imaging, Western blot in primary mouse osteoblasts and MC3T3-E1 cells\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown plus pharmacological approaches in primary cells; single lab, multiple readouts\",\n      \"pmids\": [\"30328352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Membrane cholesterol depletion (with MβCD) augments TRPV4 activation by agonist, osmotic swelling, and mechanical strain, and increases plasma-membrane TRPV4 expression. TRPV4 channels reside primarily outside cholesterol-enriched caveolin/lipid-raft domains; cholesterol repletion reverses these effects. MβCD induces TRPV4-dependent currents in Xenopus oocytes.\",\n      \"method\": \"MβCD cholesterol depletion/repletion, GSK1016790A activation assays, co-immunoprecipitation with caveolin-1, electrophysiology in Xenopus oocytes, confocal imaging in trabecular meshwork cells\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell systems, electrophysiology, Co-IP, pharmacological manipulation; single lab\",\n      \"pmids\": [\"34710431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TRPV1 and TRPV4 form functional heteromeric channel complexes in retinal microvascular endothelial cells (RMECs), as demonstrated by proximity ligation assay and patch-clamp recording. Inhibition of either channel suppresses in vitro tubulogenesis and reduces retinal neovascularization in vivo in the OIR mouse model.\",\n      \"method\": \"Proximity ligation assay, patch-clamp electrophysiology, pharmacological inhibition, in vivo OIR mouse model, in vitro angiogenesis assays\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PLA and electrophysiology establish heteromeric complex; in vitro and in vivo functional data; single lab\",\n      \"pmids\": [\"31369032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"miR-203b-3p activates the 5-HTR2B receptor, leading to PKC-dependent phosphorylation of TRPV4, which triggers itch in sensory neurons and mouse scratch behavior. Genetic deletion or pharmacological antagonism of TRPV4 attenuates this itch response.\",\n      \"method\": \"TRPV4 KO mice, pharmacological antagonism (HC067047), PKC inhibitor, Ca2+ imaging in DRG neurons, behavioral scratch assays, computer simulation of miRNA-receptor interaction\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological approaches in vivo and in neuronal Ca2+ imaging; PKC-dependent TRPV4 phosphorylation proposed mechanistically; single lab\",\n      \"pmids\": [\"36049541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TRPV4 activation induces exocytosis in melanoma cells through interactions with ER folding and vesicle trafficking proteins triggered by Ca2+ entry; this is followed by mitochondrial crista morphology changes leading to ferroptosis.\",\n      \"method\": \"TRPV4-specific agonists, co-IP to identify folding/vesicle trafficking protein interactions, live-cell vesicle imaging, mitochondrial morphology analysis in melanoma A375 cells\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — Co-IP with trafficking proteins and imaging; single lab, mechanistic connections are partially inferred\",\n      \"pmids\": [\"35456964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Endothelial-specific TRPV4 knockout protects against pressure-overload cardiac hypertrophy by enhancing coronary angiogenesis; mechanistically, TRPV4 downregulation activates matrix stiffness-dependent YAP and VEGFR2 via the Rho/ROCK/LATS kinase pathway, upregulating proangiogenic factors (VEGFα, NOS3, FGF2).\",\n      \"method\": \"Endothelium-specific TRPV4 KO mice (transverse aortic constriction model), RNA-seq, siRNA, Western blot, qPCR, confocal immunofluorescence, extracellular matrix gels of varying stiffness\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endothelium-specific KO with RNA-seq and mechanistic pathway validation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37702061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Substrate mechanics and cytoskeletal integrity modulate mechanically evoked TRPV4 currents, and TRPV4 mechanical activation is distinct from PIEZO1 activation in the same cell type; point mutations associated with TRPV4 phosphorylation and arthropathy alter mechanical (but not chemical) channel gating.\",\n      \"method\": \"Electrophysiology on substrates of varying stiffness, pharmacological cytoskeletal disruption, comparison of disease-associated point mutants for mechanical vs. chemical gating\",\n      \"journal\": \"Frontiers in bioengineering and biotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — electrophysiological reconstitution with biomaterial substrates and mutagenesis; single lab\",\n      \"pmids\": [\"33537292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Pharmacological activation of TRPV4 increases canonical TGFβ signaling in chondrocytes in a Ca2+/CamKII-dependent manner; this potentiation only occurs when TRPV4 is activated after (not before) TGFβ stimulation. RNA-seq identifies JUN and SP1 as key transcription factors mediating this crosstalk.\",\n      \"method\": \"Pharmacological TRPV4 activation/inhibition, CamKII inhibitor, TRPV4 knockdown, TGFβ reporter assays, RNA-seq in chondrocytes\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic (KD) plus transcriptomic analysis with mechanistic Ca2+/CamKII dissection; single lab\",\n      \"pmids\": [\"33805168\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TRPV4 is a polymodal, Ca2+-permeable non-selective cation channel that is directly gated by cell swelling, heat, 4α-phorbol esters (at the S1-S4/VSLD domain), and epoxyeicosatrienoic acids (via PLA2/cytochrome P450 metabolism); its pore selectivity is determined by residues Asp672, Asp682, and Met680; it physically interacts with RhoA through its N-terminal ankyrin repeat domain (suppressing both TRPV4 channel activity and RhoA activation to regulate cytoskeletal outgrowth and neurite extension), forms a functional complex with eNOS to promote vasodilation, functionally couples to TMEM16F within Ca2+ microdomains to drive cell fusion, and signals through downstream pathways including RhoA/ROCK1, Cdc42/N-WASP, AKT/Rac1, PLC/PKC, and YAP/STAT3 to regulate cytoskeletal remodeling, mechanosensing in bone and cartilage, immune cell activation (including NLRP3 inflammasome-dependent IL-1β release in macrophages), and sensory neuron-mediated pain and itch.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TRPV4 is a polymodal, Ca2+-permeable non-selective cation channel that transduces osmotic, mechanical, thermal, and chemical stimuli into Ca2+-dependent cellular responses governing cytoskeletal remodeling, vascular tone, mechanosensing, immune activation, and sensory signaling [#2, #0, #21]. The channel is directly gated by hypotonic cell swelling, producing a swelling-activated cation current with an Eisenman-IV permeability sequence distinct from volume-regulated anion channels [#3, #2], and by the synthetic agonist 4\\u03b1-PDD, which binds the base of the S1-S4 voltage-sensing-like domain (VSLD) to open the pore independently of PKC [#0, #5]; antagonists such as HC-067047 bind the same VSLD and stabilize closed states via a \\u03c0-to-\\u03b1 transition in the pore helix S6 and a fourfold-to-twofold symmetry change [#5, #6]. Pore residues Asp672, Asp682, and Met680 set Ca2+ permeability, outward rectification, and Ruthenium Red sensitivity [#1]. The cytosolic N-terminal ankyrin repeat domain physically binds RhoA, an interaction that mutually suppresses channel activity and RhoA activation to promote neurite extension; neuropathy-associated mutations disrupt this interface, and cryo-EM places RhoA on the membrane-facing surface of the ankyrin repeats [#4, #5]. Downstream of Ca2+ influx, TRPV4 drives cytoskeletal and migratory programs through RhoA/ROCK1/LIMK/cofilin [#16], Cdc42/N-WASP [#13], and AKT/Rac1 [#14], and contributes to mechanosensing and matrix-stiffness signaling via YAP [#28, #17]. TRPV4 forms functional complexes with eNOS to promote vasodilation and regulate blood pressure [#19] and couples to the scramblase TMEM16F within Ca2+ microdomains to drive cell fusion [#9]. In immune and glial cells it mediates crystal-induced NLRP3 inflammasome activation and IL-1\\u03b2 release in macrophages [#12], CaSR-coupled M1 polarization [#18], and microglial activation and motility [#21, #11], and in sensory neurons it mediates serotonin-evoked itch [#22, #26]. Channel surface density and gating are tuned by Ca2+/PI3K/PKC/RhoA-dependent endosomal trafficking [#7], membrane cholesterol content [#24], and transcriptional repression by the progesterone receptor [#8].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that the murine TRPV4 ortholog is itself an osmosensitive Ca2+-permeable channel, defining its founding function as an osmosensor rather than an accessory subunit.\",\n      \"evidence\": \"Heterologous expression with cytosolic Ca2+ measurement under hypoosmotic challenge\",\n      \"pmids\": [\"11094154\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single readout system did not resolve direct vs. indirect osmotic gating\", \"No biophysical pore characterization\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the biophysical signature of swelling-activated TRPV4 current and distinguished it from the endogenous volume-regulated anion channel, clarifying channel identity.\",\n      \"evidence\": \"Whole-cell patch-clamp with ionic substitution and ionic-strength/GTP\\u03b3S controls in HEK-293\",\n      \"pmids\": [\"11713648\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking swelling to gating not resolved\", \"Did not identify pore residues\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified a direct small-molecule agonist (4\\u03b1-PDD) and the pore residues governing ion selectivity, converting TRPV4 into a pharmacologically and structurally tractable channel.\",\n      \"evidence\": \"Patch-clamp + Ca2+ imaging with PKC dissection (4\\u03b1-PDD); site-directed mutagenesis of pore residues with reversal-potential measurements\",\n      \"pmids\": [\"11827975\", \"12093812\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Agonist binding site not localized at atomic resolution in these studies\", \"Physiological agonist remained undefined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed that TRPV4 abundance is transcriptionally controlled by the progesterone receptor, establishing hormonal regulation of channel expression.\",\n      \"evidence\": \"RT-PCR, Western blot, patch-clamp, Ca2+ imaging, siRNA, promoter-luciferase reporter in epithelial cells\",\n      \"pmids\": [\"19701771\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. indirect promoter binding not resolved\", \"Physiological contexts of PR-TRPV4 regulation limited\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected TRPV4 to cytoskeletal mechanics and cancer cell invasion, showing channel activity reshapes the actin cortex and enables transendothelial migration and serotonin-evoked itch in distinct tissues.\",\n      \"evidence\": \"siRNA/overexpression with AFM stiffness measurement and xenografts (breast cancer); TRPV4 KO behavioral and DRG Ca2+ imaging (itch)\",\n      \"pmids\": [\"27291497\", \"26763435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between channel and cortex remodeling not fully defined\", \"Itch transduction pathway upstream of TRPV4 unresolved at this stage\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapped TRPV4 onto specific migratory and mechanotransduction effector pathways (AKT/Rac1; osteoblast RANKL/NFATc1), defining downstream signaling outputs.\",\n      \"evidence\": \"Pharmacological gain/loss-of-function with phospho-signaling Western blots (glioma); siRNA/shRNA and Ca2+ imaging in osteoblasts\",\n      \"pmids\": [\"29928875\", \"30328352\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect coupling to AKT not established\", \"Contribution of co-acting channels (TRPM3) not fully separated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed TRPV4 surface density is dynamically regulated by Ca2+/PI3K/PKC/RhoA-dependent endosomal trafficking, and that TRPV4 can form heteromeric complexes with TRPV1.\",\n      \"evidence\": \"Single-molecule trafficking imaging with pathway inhibitors; proximity ligation assay and patch-clamp for TRPV1/TRPV4 heteromers\",\n      \"pmids\": [\"30728775\", \"31369032\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry of heteromers undefined\", \"Trafficking determinants on TRPV4 not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified the TRPV4 N-terminal ankyrin domain as a direct RhoA-binding interface that reciprocally controls channel activity and cytoskeletal outgrowth, providing a molecular basis for TRPV4 neuropathy.\",\n      \"evidence\": \"Unbiased interaction screen, reciprocal Co-IP, channel recordings, disease-mutant neurite assays, Drosophila rescue\",\n      \"pmids\": [\"33664271\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural details of the interface not yet resolved in this study\", \"Skeletal dysplasia mutations act through a distinct mechanism left undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanded TRPV4 into immune, glial, microdomain, and lipid-signaling roles, showing it drives crystal-induced NLRP3/IL-1\\u03b2 in macrophages, couples to TMEM16F for cell fusion, mediates thermosensitive microglial motility, and requires PLA2/CYP450/EET intermediates in microglia.\",\n      \"evidence\": \"TRPV4 KO + patch-clamp + in vivo gout models; Ca2+-microdomain electrophysiology and fusion assays; KO two-photon imaging; pharmacological PLA2/CYP450 pathway dissection\",\n      \"pmids\": [\"34663597\", \"35670667\", \"33888579\", \"33624376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physical proximity of TRPV4 to TMEM16F not structurally resolved\", \"Mechanism linking crystal sensing to TRPV4 gating undefined\", \"Source/identity of endogenous EET ligand in vivo unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined receptor-coupled and transcriptional effector arms of TRPV4 signaling, including CaSR coupling for M1 polarization, 5-HTR2B/PKC phosphorylation in itch, and YAP/STAT3-driven neuroinflammation.\",\n      \"evidence\": \"KO macrophages + pharmacology + ELISA (CaSR); KO/antagonist + DRG Ca2+ imaging + PKC inhibitor (itch); siRNA of TRPV4/YAP + seizure model (astrocytes)\",\n      \"pmids\": [\"36606511\", \"36049541\", \"35182379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PKC phosphorylation sites on TRPV4 not biochemically mapped\", \"Sequence of YAP activation relative to channel gating unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided atomic-resolution mechanism: cryo-EM placed RhoA on the ankyrin-domain surface and localized agonist/antagonist action at the VSLD with defined gating transitions, while establishing the TRPV4-eNOS vasodilatory complex and endothelial mechanotransduction roles.\",\n      \"evidence\": \"Cryo-EM of TRPV4-RhoA and ligand-bound states; Co-IP/FRET/mutagenesis + endothelial KO (eNOS); endothelium-specific KO + RNA-seq + stiffness gels (cardiac hypertrophy)\",\n      \"pmids\": [\"37353478\", \"34822720\", \"37702061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of mechanical/osmotic gating not captured\", \"eNOS-binding interface residues require independent validation\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Refined the VSLD pharmacophore by resolving two antagonist binding modes and an associated symmetry transition, informing inhibitor design.\",\n      \"evidence\": \"Cryo-EM of two antagonist complexes with electrophysiology and MD simulation\",\n      \"pmids\": [\"38659239\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional relevance of symmetry transition in native cells untested\", \"Selectivity over other TRPV channels not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis by which physical stimuli (osmotic swelling, heat, mechanical strain) are transduced into pore opening remains unresolved despite multiple ligand-bound structures.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of a mechanically/osmotically gated state\", \"Role of membrane lipids and cytoskeleton in physiological gating not structurally defined\", \"Mechanism distinguishing TRPV4 from PIEZO1 mechanotransduction unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005262\", \"supporting_discovery_ids\": [0, 2, 3]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [2, 3, 29]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 21]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [13, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 24]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [13, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 19, 16]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 18, 21]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [22, 26, 11]}\n    ],\n    \"complexes\": [\n      \"TRPV4-RhoA complex\",\n      \"TRPV4-eNOS complex\",\n      \"TRPV1-TRPV4 heteromeric channel\"\n    ],\n    \"partners\": [\n      \"RhoA\",\n      \"NOS3\",\n      \"TMEM16F\",\n      \"TRPV1\",\n      \"CAV1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}